key: cord-0722292-9zurm3fn authors: Surujballi, Julian; Shah, Hely; Hutton, Brian; AlZahrani, Mashari; Beltran-Bless, Ana-Alicia; Shorr, Risa; Larocque, Gail; McGee, Sharon; Cole, Katherine; Ibrahim, Mohammed F.K.; Fernandes, Ricardo; Arnaout, Angel; Stober, Carol; Liu, Michelle; Sienkiewicz, Marta; Saunders, Deanna; Vandermeer, Lisa; Clemons, Mark title: The COVID-19 pandemic: an opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancer date: 2021-03-23 journal: Cancer Treat Rev DOI: 10.1016/j.ctrv.2021.102188 sha: d6c83bfe3e1833e811016a7d670605caf7b005ac doc_id: 722292 cord_uid: 9zurm3fn Purpose While routine, in-person follow-up of early-stage breast cancer patients (EBC) after completion of initial treatment is common, the COVID-19 pandemic has resulted in unprecedented changes in clinical practice. A systematic review was performed to evaluate the evidence supporting different frequencies of routine follow-up. Methods MEDLINE and the Cochrane Collaboration Library were searched from database inception to July 16, 2020 for randomized controlled trials (RCTs) and prospective cohort studies (PCS) evaluating different frequencies of routine follow-up. Citations were assessed by pairs of independent reviewers. Risk of Bias (RoB) was assessed using the Cochrane RoB tool for RCTs and the Newcastle-Ottawa Quality Assessment Scale for Cohort Studies. Findings were summarized narratively. Results The literature search identified 3,316 studies, of which 7 (6 RCTs and 1 PCS) were eligible. Study endpoints included; quality of life (QoL; 5 RCTs and 1 PCS), disease free survival (DFS) (1 RCT), overall survival (OS) (1 RCT) and cost-effectiveness (1 RCT). The results showed reduction in follow-up frequency had no adverse effect on: QoL (6 studies, n=920), DFS (1 trial, n=472) or OS (1 trial, n=472), but improved cost-effectiveness (1 trial, n=472). Four RCTs specifically examined follow-up on-demand versus scheduled follow-up visits and found no statistically significant differences in QoL (n=544). Conclusion While no evidence-based guidelines suggest that follow-up of EBC patients improves DFS or OS, routinely scheduled in-person assessment is common. RCT data suggests that reduced frequency of follow-up has no adverse effects. Routine, in-person, follow-up of early stage breast cancer patients (EBC) after completion of their acute phase of treatment (i.e. surgery/radiation and/or chemotherapy) is common. The goals of such follow-up vary, including early detection of recurrence, evaluation and treatment of therapy-related complications, motivation of patients to continue therapy, and provision of on going support. [1] We are not aware of any evidence that routine follow-up of asymptomatic patients has any impact on either disease free survival (DFS) or overall survival (OS). This type of follow-up does, however, have significant resource implications for health care systems as the prevalence of breast cancer continues to rise [2] [3] . The COVID-19 pandemic has placed unprecedented pressure on health care systems around the world. It has been demonstrated through observational studies that patients with active or previous malignancy suffer high rates of mortality from COVID-19, irrespective of whether they are actively receiving anticancer therapy [4, 5] . This necessitates harm reduction strategies that enable the safe provision of cancer care to continue, through such strategies as testing for SARS-CoV-2 prior to starting anticancer therapy, upon admission to oncology wards or palliative care units, and for ambulatory patients with certain high risk features [6] [7] [8, 9] . The rapid introduction of physical distancing protocols has resulted in both patients and health care providers re-evaluating how clinics are run. This has led to a significant increase in the use of virtual visits as well as decrease in in-person evaluation and examination of patients [10, 11] . The COVID-19 pandemic thus provides a unique motivation to re-evaluate the totality of evidence around the frequency and type of follow-up [12] . While the National Institute for Health and Care Excellence (NICE) recommends avoidance of routine follow-up in asymptomatic patients [13] , other national and international practice guidelines recommend regular follow-up with health care providers, sometimes as often as every 3-6 months, for several years (Table 1 ) [1, [14] [15] [16] [17] [18] . Given the importance of providing evidence-based follow-up care during the COVID-19 pandemic, this systematic review was performed to provide up-to-date evidence around optimal recommendations in terms of both frequency and duration of follow-up care. In addition, we hoped to identify areas where further studies are needed. A protocol was prepared a priori and was registered with the Open Science Framework [19] [20] [21] . Grey literature sources were not accessed. There were no protocol deviations. Data sources for the search were English language journal publications from MEDLINE and the Cochrane Collaboration Library published from database inception until July 16, 2020 . The search included terms related to breast cancer and follow-up; the full search strategy is provided in Appendix A and was designed and implemented by an information specialist (RS). The population of interest included women with breast cancer who had completed the initial intensive phase of adjuvant therapy (i.e. after completion of surgery, chemotherapy/anti-HER2 therapy, radiotherapy, and commencement of endocrine therapy, if hormone receptor positive). We included randomized controlled trials (RCTs) and prospective cohort studies (PCSs) whose primary objective was assessing different intervals between follow-up appointments after an initial phase of adjuvant therapy. There were no restrictions in type of setting, the type of health care professional, duration of follow-up. Outcomes of a priori interest consisted of DFS, OS, QoL (broadly including validated scales or any other outcome pertaining to anxiety, depression and worry), cost-effectiveness, number of investigations ordered, treatment or investigation related harm as classified by each study's authors including type of harm, frequency and grade (if applicable), and patient satisfaction. The reference lists of relevant clinical guidelines from ASCO, ESMO, and NCCN were also reviewed for any relevant studies not found by our search [1, 15, 16] . Screening of titles and abstracts was performed Primary outcomes of interest were OS and DFS. Relevant secondary outcomes were QoL, measures of cost effectiveness, number of investigations ordered, treatment or investigation related harm as classified by each study's authors including type of harm, frequency and grade (if applicable), and patient satisfaction. Other extracted data items included study/publication characteristics (study title, authors, location, funding source, journal, publication date) study design details, study sample size, patients' baseline demographics and disease characteristics , therapy received (adjuvant or neoadjuvant hormone therapy, chemotherapy/anti-HER-2/neu therapy, radiation, mastectomy vs lumpectomy) including specific agents used, sequence of therapy (if applicable), followup duration, setting, provider type and appointment schedule, and components of surveillance (History, physical exam, blood work, imaging, other investigations). Risk of bias (RoB) was assessed using the Cochrane RoB 2 tool [22] for RCTs and the Newcastle-Ottawa Scale [23] for cohort studies. The completed review includes a descriptive summary of findings from these assessments (with detailed evaluations provided in Appendices D1 and D2 respectively), which were considered in the context of drawing interpretations of the study data. Measures of central tendency and dispersion for continuous outcomes (including means, standard deviations, medians and ranges) and the numbers of patients experiencing events (and sample size) were collected when available. For time-to-event outcomes, hazard ratios with corresponding 95% confidence intervals were collected. A descriptive summary of characteristics of the included studies was generated addressing the populations, comparators, outcomes and design features of the included studies. The research team discussed the homogeneity of the studies in terms of their study populations and methods. Presentation of data was appropriately grouped according to the treatment comparisons made within studies and according to the interval duration between follow-up visits. Descriptive summary and tables were used to present study-level findings. The appropriateness of meta-analysis was considered in light of the variability between studies in terms of clinical and methodologic characteristics, and the research team felt a descriptive approach to synthesis was most appropriate. A total of 3,316 citations were identified for review by the electronic literature search. A total of 3,288 were excluded during screening of titles/abstracts due to ineligibility, leaving 28 citations for full text review. Of these, 21 studies were excluded because they were not clinical trials or PCS (n=12), involved interventions not related to varying follow-up intervals (n=6), were published in a non-English language (1), or the full text reports could not be accessed (n=2). In total, 7 studies met the a priori eligibility criteria; Figure 1 depicts the study selection process. Study characteristics are outlined in Table 2 , while patients' baseline characteristics are detailed in Table 3 . Of the 7 studies included, 6 studies were RCTs and 1 PCS. The studies were published between 1997 and 2020 ( Table 2) . Four studies examined follow-up on-demand [24] [25] [26] [27] , 1 study examined various predetermined follow-up schedules [28] , 1 study tailored the follow-up frequency based on risk of recurrence [29] , and 1 examined used follow-up only after mammography [30] . Three studies excluded patients who received chemotherapy [25, 27, 30] , 1 of which included only patients on tamoxifen alone or no active therapy [30] . Two studies examined quality of life as a primary outcome [25, 27] and 1 as a secondary outcome [24] . Similarly, 2 studies examined psychological impact as primary outcomes [27, 29] , 3 studies explored patient satisfaction as primary outcomes [24, 29, 30 ] and 1 as a secondary outcome [27] . One study examined survival as a primary outcome [28] , and 1 study examined recurrences and method of detection as a secondary outcome [26] . One study examined cost effectiveness and healthcare utilization as a primary outcome [28] and 2 as a secondary outcomes [24, 29] . Due to the differences outlined above in inclusion criteria, variations in experimental follow-up strategies, absence of standard follow-up schedules being specified, and differences in study outcomes, the evidence was judged by the study team to be too heterogeneous for meta-analysis. As of such, a descriptive approach to summarize findings was used. Findings from risk of bias appraisals are provided in Appendix D. All RCTs were adequate in random sequence generation. While allocation concealment was not explicitly mentioned in any study, there was specific concern regarding Kokko et al., 2005 [28] , where the patient population appeared to have been studied in several different trials. Minor protocol deviations were observed in Riis et al., 2020[24] who excluded some patients for reasons that were logical but outside their prespecified exclusion criteria, Kokko et al., 2005[28] who called a small number of patients outside of the study protocol but accounted for this in analysis, Brown et al., 2002[27] who did not collect data on some patients enrolled, and Gulliford, et al., 1997[30] who saw three patients who decided to pursue an alternative follow-up schedule. None of these deviations were expected to significantly impact overall findings. By the nature of the intervention, blinding of studies was not possible. Within the limitations of assessment without access to the original study protocols, here were no concerns regarding significant losses to follow-up, or incomplete outcome data or selective reporting except for Kokko et al., 2005[28] who reported no differences between arms in the prespecified outcome of DFS, without described data. This study also reports on OS which was not a preplanned study outcome. Per-protocol analysis was used by Riis et al., 2020[24] , Brown et al., 2002[27] , and Gulliford et al., 1997[30] . The remaining studies appear to have used intention to treat but were not explicit in their description. Risk of bias was deemed high for Kokko et al., 2005[28] , intermediate for Gulliford et al., 1997[30] and low for all other RCTs. One single-arm prospective trial, van Hezewijk, et al. 2014 [29] , was assessed using the Newcastle-Ottawa Scale and was found to have high risk of bias, largely due to the nature of single-arm studies. Six studies examined QoL metrics. Riis et al. (2020) [24] conducted a pilot RCT which enrolled 134 postmenopausal women with hormone positive EBC after primary surgery and scheduled for at least five years of adjuvant endocrine therapy. Patients were randomized to either standard follow-up with prescheduled follow-up every 6 months (n=69) or individualized follow-up with electronic patient reported outcomes (reports from the patient evaluating her health status) to screen for the need of consultations (n=65). The primary outcome was satisfaction with the assigned follow-up care and unmet needs as measured by a Patient Experience Questionnaire (PEQ) administered every three months for two-years. Secondary outcomes were use of consultations, adherence to treatment (audit of electronic medical records) and QoL (EORTC QLQ-C30, EORTC QLQ-BR23). At the end of the study period, no statistically significant differences were reported in relation to satisfaction, unmet needs, treatment adherence or QoL. Findings were summarized graphically but numeric estimates were not provided for QoL endpoints. Kirshbaum et al. (2017) [25] conducted an RCT that evaluated women newly diagnosed with stage 1 or 2 EBC, treated with curative intent and considered clinically to be at low risk of recurrence. The study excluded women who received adjuvant chemotherapy, those participating in other trials that required an alternate follow-up protocol or having a high risk for recurrence. There were 112 patients randomized to either standardized Patients in the point of need access group were given the option of returning to 6-month clinical review or not. Of these patients, 5 of 107 chose to return to 6-monthly review. Brown et al. (2002) [27] reported the results of a RCT of 61 women previously treated for stage I EBC randomized to standard clinic follow-up versus patient-initiated follow-up with written information on signs and symptoms being provided. The exact schedule followed in the control arm was not provided, though at the time of recruitment patients were being followed either every 4 months, 6 months or yearly. The primary outcome was cancer and breast cancer specific QoL (EORTC QLQ-C30, QLQ-BR23) and psychological morbidity (HAD scale). The secondary outcome was satisfaction with follow-up as assessed by a structured interview. Median scores with ranges were provided in table form for all categories and time points, but no easily communicable summative qualitative score was provided. The study reported no major differences in QoL (no p-values provided) apart from observing higher scores for arm (p=0.028) and breast symptoms (p=0.033) in the control group. There were no differences between groups in anxiety (p=0.069) or depression (p=0.232). More women in the standard clinic group reported reassurance of being assessed as advantages (p=0.003) whereas more women in the patient-initiated follow-up group reported convenience as an advantage (p=0.000). Gulliford et al. (1997) [30] mammogram only) rather than increasing follow-up (n=7 control, n=10 mammogram only). No increased use of local practitioner services or telephone triage was apparent in the cohort randomized to less frequent follow-up by specialists. Of eligible patients, 7.1% declined participation. Comparing patient satisfaction in the conventional versus mammogram-only visit groups, reassurance from specialist follow-up was reported in 94% versus 88% of patients respectively, preference for more frequent follow-up in 11% versus 16% respectively, and preference for less frequent follow-up in 25% versus 35% respectively (no p-value provided). One study had a primary endpoint of DFS. Kokko, et al. (2005) [28] was a four-arm RCT investigating different follow-up strategies. The 472 patients were randomized to either follow-up every 3 months with routine investigations (n=125), every 6 months with routine investigations (n=118), every 3 months with investigations only when indicated (n=114), or every 6 months with investigations only when indicated (n=115). Routine investigations included complete blood count, calcium, sedimentation rate, alkaline phosphatase, alanine aminotransferase and Ca 15-3 at every visit, chest X-ray every sixth month, and liver ultrasound and bone scan every second year. One primary outcome was DFS. Patients were followed for 5 years or until relapse, whichever came first. The investigators reported that neither frequency of visit nor intensity of investigations had any effect on DFS or OS, but did not report any quantitative effect size. Reference was made to a previous study by this group in which the utility of x-rays in detecting recurrence was examined in the same 472 patients in which no differences to DFS or OS were found. Kokko, et al. (2005) [28] investigated cost per arm, per patient and per recurrence as primary outcomes. The study was performed at a single center in Finland. The cost per patient and recurrence was calculated by dividing the total cost in that study arm by the number of patients with recurrences in that arm, respectively. The authors reported that mean cost per patient and per recurrence for those receiving follow-up every 3 months with investigations as indicated was 1050€ and 4864€ respectively, as compared to 2269€ and 4166€ for those receiving follow-up every 6 months with investigations as The secondary outcome of Sheppard, et al. (2009) [26] was the number of recurrences and methods of detection. Nine (9) recurrences were detected during the study period, 5 of 112 patients in the experimental group and 4 of 112 in the control group. The presentation of recurrences and short symptom history demonstrate that the recurrences observed were unlikely to have been detected at a routine visit. Interestingly, one patient in the control group identified a local chest wall recurrence but waited two months until her next scheduled review. van Hezewijk, et al. (2014) [29] examined incidence and time to detection of local recurrences as secondary outcomes. A total of 12 recurrences were found with 6 each in the low and intermediate risk groups. In the low risk group two recurrences were local, 3 were contralateral breast cancer and 1 patient had distant metastases. Two recurrences were found by the patient, 1 by physical examination and 3 were asymptomatic and found on imaging. In the intermediate risk group, 1 recurrence was local, 1 was in a supraclavicular node and 5 were contralateral breast cancer. Two recurrences were found by the patient and 4 were asymptomatic and found on imaging. The median time to detection of recurrence was 18 months in the low risk group and 32 months in the intermediate group. While there was no control group to compare to standard follow-up, it is notable that the time to detection of recurrence was longer in the group with more frequent follow-up visits. Routine, in-person follow-up of EBC after completion of their acute phase of treatment is common. Despite differences in patient and health care provider perceptions around the role of routine follow-up [12] and the recommendations from guideline groups for what this follow-up should entail [1, 15, 16] , there is no evidence that routine follow-up of asymptomatic patients has any impact on either DFS or OS [1, [14] [15] [16] [17] . This type of follow-up has significant resource implications for health care systems [31] [32] [33] . Data from our own institution, that sees approximately 1000 new breast cancer patients a year, has around 50,000 breast cancer follow-up visits each year (Kate Duke, personal communication 2020). The COVID-19 pandemic has suddenly made this issue critical, and health care providers have been forced to change the way in which they assess their patients and thus presents an opportunity to rethink and harmonise clinical practice with the available evidence base. The purpose of this systematic review was to provide evidence as to how we can change the nature of our follow-up practices safely. The data provided from these studies demonstrate that once the initial intense phase of treatment is complete, reducing the frequency of follow-up visits had no detrimental effects on either patient QoL or caused anxiety [24] [25] [26] [27] 29, 30] . Of interest, many patients did not wish to return to the conventional schedule after the trial period [26] . Only one study evaluated DFS and OS, and while they reported no difference between different follow-up intervals, quantitative data was not provided [28] . The same study also demonstrated that less frequent follow-up is more cost-effective [28] . Also of interest was that in all 5 studies that compared routine prescheduled follow-up with follow-up triggered by symptoms/surveillance investigations there was no significant difference in clinically important outcomes [24] [25] [26] [27] [28] [29] [30] . Our findings are consistent with the growing body of evidence that deintensification of breast cancer follow-up is safe and effective. It has been shown that nurse or general practitioner led follow-up is no better than specialist follow-up, a message that has been reinforced by some institutions and regulatory bodies [34] [35] [36] [37] [38] . Several studies have also demonstrated that additional use of radiographic imaging, tumor markers and other serologic testing in the absence of concerning symptoms is of no benefit [39, 40] . Perhaps most notably, there is evidence that early detection of breast cancer does not necessarily lead to better outcomes [13] . This information must be considered when recommending a follow-up protocol. While some groups and regulatory bodies have reflected this in their recommendations (Table 1) , the suggested frequency of follow-up in these guidelines is either higher than that suggested by evidence or not specified at all. In light of our data, we believe it would be appropriate for groups such as Choosing Wisely and regulatory bodies to consider recommending risk-adapted follow-up plans in the absence of evidence that symptom-oriented strategies are inferior to intensive schedules. There are several limitations in interpreting this data. Given the high prevalence of EBC, it was surprising that many of the trials were so small and that so little prospective data on DFS or OS were reported. Second, many studies did not state what schedule was followed in the control arm and thus require us to assume that evidence-based guidelines recommendations were followed. Third, while these studies selected for early stage and overall lower-risk disease, the risk of recurrence in breast cancer is nuanced and is impacted by more than pathologic staging with factors such as hormone expression, HER-2/Neu expression, gene expression profile, type of treatment are important and none of the studies stratified patients based on these factors. Fourth, for studies examining on-demand follow-up, it is not clear based on this data what information effectively educates patients when to trigger visits. Fifth, there was significant variability in study designs and endpoints that precluded the ability to pursue quantitative syntheses. Similarly, outcome data was often not reported in detail with relevant, meaningful numeric data frequently being absent. There is the issue of selection bias as patients who consent to studies in which they would be randomized to less frequent follow-up may be more likely to accept this change than the general population. Lastly, the data presented does not address the role of virtual visits. In all studies identified, every physician visit was accompanied by a physical exam, which is naturally absent from virtual follow-up. The role of telemedicine for example in this setting remains unclear. Many of these issues should be addressed in future trials. These could evaluate not just impact of different follow-up strategies on quality of life and whether groups with different risk of recurrence benefit from different follow-up strategies but also the Health Economic aspects of different strategies. Additionally, it is important to examine what follow-up frequency is required to maintain adherence to long-term therapy and to manage treatment toxicity. In addition, it is likely that virtual visits will remain even after the COVID-19 pandemic, so studies will need to address the issue of missing physical examinations at the time of follow-up, especially as the fraction of recurrences detected by clinical examination is falling [41] . Similarly, there is the issue of over examination as some guidelines even recommend yearly gynecologic assessment for women on tamoxifen based on expert consensus [1, 15] . While no evidence-based guidelines suggest that follow-up of EBC patients improves either DFS or OS, routinely scheduled in-person assessment is common. The totality of the randomized data suggests that reduced frequency of follow-up has no adverse effects and more specifically, on-demand follow-up is associated with lower cost-perrecurrence detected than scheduled follow-up. Furthermore, it does not appear that follow-up must be specifically with a physician. While more trials are clearly required most evidence would suggest that moving to a model based upon follow-up to be triggered by patient demand or to review results of mammography is likely the most effective for implementing immediately. While the pandemic will pass, we need to ensure effective strategies are put in place. Funding: This systematic review was internally funded from the REthinking Clinical Trials (REaCT) program. The authors declare that they have no conflict of interest. Ethics approval: Ethics approval was not required for this systematic review. This systematic review did not involve individual participation and therefore informed consent is not applicable. Availability of data and material: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. The review team included all authors. State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in metaanalysis) Yes -Page 5 Data collection process 11c Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators Yes -Page 5 List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications Yes -Page 5 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale Yes -Page 6 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis Baseline disease characteristics (TNM stage, grade, and receptor status including estrogen, progesterone and HER-2/neu)  Therapy received (Adjuvant or neoadjuvant hormone therapy, chemotherapy, anti-HER-2/neu directed therapy, radiation therapy, bisphosphonates, mastectomy vs lumpectomy) including specific agents used  Sequence of therapy (if applicable)  Follow-up duration, setting, provider type and appointment schedule  Components of surveillance (History, physical exam, blood work, imaging, other investigations)  Outcomes: Data related to overall survival, disease-free survival, quality of life, cost-benefit, number of investigations ordered, treatment related harm, investigation related harm, and patient satisfaction. Measures of central tendency and dispersion for continuous outcomes (including means, standard deviations, medians and ranges) and the numbers of patients experiencing events (and sample size) will be gathered. Overall bias Randomization by a computer-generated sequence. Per-protocol analysis was used. This patient population appears to have been randomized in a separate study. One patient who was randomized was lost to follow up and excluded from analysis. Patients who decided to pursue an alternative schedule of appointments or mammograms than was specified in the trial protocol were excluded. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Projected estimates of cancer in Canada in 2020 Cancer statistics Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer COVID-19 Testing in Patients with Cancer: Does One Size Fit All? Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2 Low prevalence of IgG antibodies to SARS-CoV-2 in cancer patients with COVID-19 Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19 Teleoncology or telemedicine for oncology patients during the COVID-19 pandemic: The new normal for breast cancer survivors? Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an Alternative methods of follow up in breast cancer: A systematic review of the literature Improving outcomes in breast cancer -Cancer service guideline (CSG1) Cancer Care Ontario's Position on Guidelines for Breast Cancer Well Follow-up Care NCCN Guidelines Version 2.2020 Breast Cancer Breast cancer follow-up and management after primary treatment: American society of clinical oncology clinical practice guideline update Evidence Summary: Breast Screening for Survivors of Breast Cancer A scoping review characterizing "Choosing Wisely®" recommendations for breast cancer management Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols ) 2015 checklist : recommended items to address in a systematic review protocol * RoB 2: A revised tool for assessing risk of bias in randomised trials The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses n Satisfaction with care and adherence to treatment when using patient reported outcomes to individualize follow-up care for women with early breast cancer-a pilot randomized controlled trial Open access follow-up care for early breast cancer: a randomised controlled quality of life analysis Breast cancer follow up: A randomised controlled trial comparing point of need access versus routine 6-monthly clinical review Patient Initiated Follow Up Follow-up cost of breast cancer patients with localized disease after primary treatment: A randomized trial Feasibility of tailored follow-up for patients with early breast cancer Popularity of less frequent follow up for breast cancer in randomised study: Initial findings from the hotline study Evidence to support a change in follow-up policy for patients with breast cancer: Time to first relapse and hazard rate analysis Intensive followup for women with breast cancer: Review of clinical, economic and patient's preference domains through evidence to decision framework Clinical and organizational issues in the management of surviving breast and colorectal cancer patients: Attitudes and feelings of medical oncologists Randomized trial of long-term follow-up for early-stage breast cancer: A comparison of family physician versus specialist care Expert Panel on effective ways of investing in Health (EXPH) World Health Organization. Taking stock: Task shifting to tackle health worker shortages. World Heal Organiation Heal Community health workers and early detection of breast cancer in low-income and middle-income countries: A systematic scoping review of the literature Nurse-led follow-up care for cancer patients: What is known and what is needed Follow-up strategies for women treated for early breast cancer Follow-up strategies for women treated for early breast cancer Follow-up in breast cancer : does routine clinical examination improve outcome ? A systematic review of the literature Clinical Studies 20 clinical trials as topic.sh. (225327) 21 trial.ti. (852906) 22 prospective studies/ (1142231) 23 prospective*.tw,kw Longitudinal Studies/ (263921) * up adj2 (interval* or schedule* or program* or test* or appointment? or strateg* or method? or visit? or frequen* or model? or service? or surveillance or clinic*)).tw. (229561) 32 follow up.ti. or follow up care.tw. (267085) 33 ((survivor* or patient*) adj2 (follow* up or surveillance)).tw treatment or after treatment or mammograph* or imaging) adj3 surveillance).tw. (6127) * up adj2 (interval* or schedule* or program* or test* or appointment? or strateg* or method? or visit? or frequen* or model? or service? or surveillance or clinic*)).tw. (229561) 55 (follow* up adj2 (interval* or schedule* or program* or test* or appointment? or strateg* or method? or visit? or frequen* or model? or service? or surveillance or clinic*)).kw. (3740) 56 ((survivor* or patient*) adj2 (follow* up or surveillance)).tw Cancer Survivors/ and follow up.tw,kw Population Surveillance/ (239906) 60 surveillance.ti,kw treatment or after treatment or mammograph* or imaging) adj3 surveillance).tw. (6127) 62 ((post treatment or after treatment or mammograph* or imaging) and surveillance).kw breast or mamma or mammary) adj3 (cancer* or carcinoma* or neoplasm* or tumor* or tumour*)).tw. (871194) 3 ((breast or mamma or mammary) and (cancer* or carcinoma* or neoplasm* or tumor* or tumour*)).kf. (59731) 4 1 or 2 or 3 (1074817) 5 (follow* up adj2 (interval* or schedule* or program* or test* or appointment? or strateg* or method? or visit? or frequen* or model? or service? or surveillance or clinic*)).tw. (229561) 6 (follow* up and (interval* or schedule* or program* or test* or appointment? or strateg* or method? or visit? or frequen* or model? or service? or surveillance or clinic*)).kf. The authors declare that they have no conflict of interest.